Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 12, 2024

BUY
$161.01 - $317.85 $8.46 Million - $16.7 Million
52,557 Added 437.98%
64,557 $20.4 Million
Q3 2023

Nov 13, 2023

BUY
$164.66 - $218.08 $1.98 Million - $2.62 Million
12,000 New
12,000 $2.03 Million
Q3 2022

Nov 14, 2022

SELL
$123.79 - $277.42 $737,664 - $1.65 Million
-5,959 Reduced 69.27%
2,644 $603,000
Q2 2022

Aug 11, 2022

SELL
$93.97 - $143.33 $14,283 - $21,786
-152 Reduced 1.74%
8,603 $1.09 Million
Q1 2022

May 16, 2022

BUY
$98.9 - $132.37 $145,284 - $194,451
1,469 Added 20.16%
8,755 $1.11 Million
Q4 2021

Feb 11, 2022

BUY
$110.64 - $159.4 $806,123 - $1.16 Million
7,286 New
7,286 $954,000
Q4 2019

Feb 14, 2020

SELL
$11.44 - $123.99 $356,561 - $3.86 Million
-31,168 Closed
0 $0
Q3 2019

Nov 14, 2019

BUY
$16.05 - $27.35 $500,246 - $852,444
31,168 New
31,168 $509,000

Others Institutions Holding KRTX

About Karuna Therapeutics, Inc.


  • Ticker KRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 33,965,000
  • Description
  • Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate is KarXT, an oral modulator of muscarinic receptors that is in Phase III clinical trial for the treatment of acute psychosis in patients wi...
More about KRTX
Track This Portfolio

Track Hsbc Holdings PLC Portfolio

Follow Hsbc Holdings PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Hsbc Holdings PLC, based on Form 13F filings with the SEC.

News

Stay updated on Hsbc Holdings PLC with notifications on news.